Ali Erginay · enciclopedia

Publicaciones › Retinopatía diabética: clínica, función y progresión

Effects of Topically Administered Neuroprotective Drugs in Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial

Efectos de fármacos neuroprotectores administrados de forma tópica en las primeras etapas de la retinopatía diabética: Resultados del ensayo clínico EUROCONDOR

Año2018
FuenteDiabetes
Tipoarticle
Autores (85)Rafael Simó, Cristina Hernández, Massimo Porta, Francesco Maria Bandello, Jakob Grauslund, Simon Peter Harding, S J Aldington, Catherine A. Egan, Ulrik Frydkjær-Olsen, José García‐Arumí, Jonathan M. Gibson, Gabriele E. Lang, Rosangela Lattanzio, Pascale Massin, Edoardo Midena, Berta Ponsati, Luísa Ribeiro, Peter Henry Scanlon, Conceição Lopes Lobo, Miguel Angelo Costa, José Guilherme Cunha-Vaz, Rafael Simó, Cristina Hernández, Marta García‐Ramírez, E. van Reck, E. Gil, M. Morillas, José Guilherme Cunha-Vaz, Luísa Ribeiro, Conceição Lopes Lobo, M.A. Costa, Sandrina Gonçalves Nunes, João Figueira, Inês Pereira Marques, C. Neves, C. Schwartz, Massimo Porta, Marina Trento, Olga Durando, S. Merlo, Francesco Maria Bandello, Rosangela Lattanzio, Ilaria Zucchiatti, Jakob Grauslund, Ulrik Frydkjær-Olsen, Simon Peter Harding, Peter Henry Scanlon, S J Aldington, Va Jones, L. Johnson, S. Carter, John Spurway, Catherine A. Egan, Simona Degli Esposti, Lauren Leitch-Devlin, V. Rocco, Angela Rees, José García‐Arumí, Miguel Ángel Zapata, Anna Boixadera, C. Macià, Laura Distéfano, T. Torrent, F. Casals, N. de Dios, Jonathan M. Gibson, Gabriele E. Lang, W. Jens-Ulrich, E. Christian, K. Adnan, Pascale Massin, Ali Erginay, Edoardo Midena, Stela Vujosevic, Elisabetta Pilotto, Evelyn Longhin, Enrica Convento, Berta Ponsati, Jimena Fernández‐Carneado, S. Arrastia-Casado, S. Orgué, Dolores T. Ramírez-Lamelas, Ana Almazán-Moga, A. Salvà, L. Riera
Posición de Erginay72 de 85
Citas117 (OpenAlex)
EnlacesDOI 10.2337/db18-0682 · PubMed 30389750 · OpenAlex · Texto completo en acceso abierto
LíneasCribado, telemedicina (OPHDIAT) y epidemiología de la retinopatía diabética Retinopatía diabética: clínica, función y progresión

En pocas palabras

Se estudió el efecto de dos fármacos neuroprotectores en pacientes con diabetes tipo 2. Los resultados mostraron que, aunque no hubo un efecto general, estos fármacos podrían prevenir el empeoramiento de la disfunción retiniana en pacientes que ya la padecen. El estudio sugiere que la detección de esta disfunción es crucial para identificar a los pacientes que podrían beneficiarse de un tratamiento neuroprotector.

Resumen divulgativo generado automáticamente a partir del resumen original; puede contener imprecisiones.

Resumen original

The primary objective of this study was to assess whether the topical administration of two neuroprotective drugs (brimonidine and somatostatin) could prevent or arrest retinal neurodysfunction in patients with type 2 diabetes. For this purpose, adults aged between 45 and 75 years with a diabetes duration ≥5 years and an Early Treatment of Diabetic Retinopathy Study (ETDRS) level of ≤35 were randomly assigned to one of three arms: placebo, somatostatin, or brimonidine. The primary outcome was the change in implicit time (IT) assessed by multifocal electroretinography between baseline and at the end of follow-up (96 weeks). There were 449 eligible patients allocated to brimonidine (n = 152), somatostatin (n = 145), or placebo (n = 152). When the primary end point was evaluated in the whole population, we did not find any neuroprotective effect of brimonidine or somatostatin. However, in the subset of patients (34.7%) with preexisting retinal neurodysfunction, IT worsened in the placebo group (P < 0.001) but remained unchanged in the brimonidine and somatostatin groups. In conclusion, the topical administration of the selected neuroprotective agents appears useful in preventing the worsening of preexisting retinal neurodysfunction. This finding points to screening retinal neurodysfunction as a critical issue to identify a subset of patients in whom neuroprotective treatment might be of benefit.